Sagimet Biosciences Inc - Series A —— 季度财务数据 (NASDAQ:SGMT) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

经营活动产生的现金 -11.02 M-14.54 M-9.1 M-10.18 M-11.83 M -45.65 M 投资活动产生的现金 9.85 M3.41 M-13.29 M75 K14.36 M 4.56 M 融资活动产生的现金 0104.85 M-27 K274 K0 — 自由现金流 -11.02 M-14.54 M-9.1 M-10.18 M-11.83 M -45.65 M

新闻

Citizens重申Sagimet Biosciences股票评级,MASH研发取得进展

Citizens reiterates Sagimet Biosciences stock rating on MASH progress

Oppenheimer重申Sagimet股票评级,看好MASH试验进展

Oppenheimer reiterates Sagimet stock rating on MASH trial progress

Sagimet生物科学股票在痤疮药物安全性数据积极后上涨

Sagimet stock rises after positive Phase 3 safety data for acne drug

Ascletis reports positive long-term safety data for acne drug denifanstat

Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT)

Sagimet reports positive Phase 1 results for MASH combination therapy

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

歌礼制药-B(01672)：同类首创FASN抑制剂地尼法司他(ASC40)治疗痤疮的新药上市申请获国家药监局受理

Sagimet Biosciences executive chairman sells $290k in shares